Shire's Gaucher drug has edge over rival in trial

LONDON Thu Jun 28, 2012 4:04pm IST

Related Topics

Stocks

   

LONDON (Reuters) - Shire's Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi's Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.

The findings from the Shire-sponsored study, made public at a European Working Group on Gaucher Disease in Paris, may help Shire differentiate its product from Cerezyme, which is made by Sanofi's Genzyme unit.

Gaucher disease is a rare genetic disorder affecting some 10,000 patients worldwide. Patients with the disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

For many years Genzyme dominated the Gaucher market with its drug Cerezyme, at one point the most expensive drug in the world costing more than $200,000 a year.

But competition is now increasing. In addition to Vpriv, there is also another Gaucher drug called Elelyso from Protalix Biotherapeutics and Pfizer, which was approved by U.S. regulators in May but was rebuffed in Europe last week.

Ari Zimran of the Hebrew University and Hadassah Medical School, Jerusalem, said the study results showed Vpriv was effective in treating key markers of Gaucher-related bone disease.

Clinically and statistically significant improvements in bone measurements were seen at nine months of treatment with Vpriv but not with Cerezyme.

(Reporting by Ben Hirschler)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS EXCLUSIVE

HEALTH SHOWCASE

Marital Connection

Marital Connection

Spouse personality may affect career success  Full Article 

Influenza Vaccines

Influenza Vaccines

Plant-based vaccines challenge big pharma for $3 billion flu market  Full Article 

Ebola Outbreak

Ebola Outbreak

Traveler from Liberia is first Ebola patient diagnosed in U.S.  Full Article 

Birth Control

Birth Control

Long-acting reversible contraceptives best for teens: pediatricians.  Full Article 

Childhood Obesity

Childhood Obesity

Antibiotics in infancy may be linked to childhood obesity: study.  Full Article 

MERS Update

MERS Update

Austria reports first MERS case in Saudi national: media.  Full Article 

Sinusitis Drug

Sinusitis Drug

Sanofi-Regeneron drug has positive trial results in chronic sinusitis.  Full Article